S4498 From Liver to Nasal Drip: Epistaxis Unveils Itself as a Novel Complication in MASH Cirrhosis

John Michael Vincent Coralde,Sukhman Dhaliwal,Sandesh Karki,Ali Ghorbani,Sina Bagheri,Evelyn Aldana,Indraneel Chakrabarty
DOI: https://doi.org/10.14309/01.ajg.0001047360.54434.15
2024-10-26
The American Journal of Gastroenterology
Abstract:Epistaxis is a common symptom in patients with MASH (Metabolic Dysfunction-Associated Steatohepatitis) cirrhosis, with a prevalence of 10%-25%. This is higher than the prevalence of epistaxis in patients with alcoholic cirrhosis or in the general population. The most common risk factors for epistaxis with patients with MASH cirrhosis are portal Hypertension, coagulopathy, and platelet dysfunction according to Terracciano et al. Epistaxis can be a significant clinical problem in patients with MASH cirrhosis. It can lead to anemia, hemodynamic instability, and even death.
gastroenterology & hepatology
What problem does this paper attempt to address?